166 related articles for article (PubMed ID: 11506488)
1. Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients.
Bensmaïne MA; Marty M; de Gramont A; Brienza S; Lévi F; Ducreux M; François E; Gamelin E; Bleiberg H; Cvitkovic E
Br J Cancer; 2001 Aug; 85(4):509-17. PubMed ID: 11506488
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
[TBL] [Abstract][Full Text] [Related]
3. Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer.
Sørbye H; Glimelius B; Berglund A; Fokstuen T; Tveit KM; Braendengen M; Øgreid D; Dahl O
J Clin Oncol; 2004 Jan; 22(1):31-8. PubMed ID: 14701765
[TBL] [Abstract][Full Text] [Related]
4. Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer.
Ramanathan RK; Clark JW; Kemeny NE; Lenz HJ; Gococo KO; Haller DG; Mitchell EP; Kardinal CG
J Clin Oncol; 2003 Aug; 21(15):2904-11. PubMed ID: 12885808
[TBL] [Abstract][Full Text] [Related]
5. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer.
Bleiberg H; de Gramont A
Semin Oncol; 1998 Apr; 25(2 Suppl 5):32-9. PubMed ID: 9609106
[TBL] [Abstract][Full Text] [Related]
8. Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/-folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients.
Bensmaïne ; de Gramont A; Brienza S; Marty M; Lévi F; Ducreux M; François E; Gamelin E; Bleiberg H; Bleuzen P; Simon J; Cvitkovic E
Eur J Cancer; 2000 Dec; 36(18):2335-43. PubMed ID: 11094307
[TBL] [Abstract][Full Text] [Related]
9. Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer.
Popov I; Radosevic-Jelic L; Jezdic S; Milovic M; Borojevic N; Stojanovic S; Stankovic V; Josifovski T; Kezic I
J BUON; 2008; 13(4):505-11. PubMed ID: 19145671
[TBL] [Abstract][Full Text] [Related]
10. Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis.
Seo HY; Kim DS; Choi YS; Sung HJ; Park KH; Choi IK; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
Cancer Chemother Pharmacol; 2009 Feb; 63(3):433-9. PubMed ID: 18398608
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program.
Brienza S; Bensmaïne MA; Soulié P; Louvet C; Gamelin E; François E; Ducreux M; Marty M; André T; de Braud F; Bleiberg H; Ségal V; Itzhaki M; Cvitkovic E
Ann Oncol; 1999 Nov; 10(11):1311-6. PubMed ID: 10631458
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
Novarino A; Satolli MA; Chiappino I; Giacobino A; Bellone G; Rahimi F; Milanesi E; Bertetto O; Ciuffreda L
Am J Clin Oncol; 2009 Feb; 32(1):44-8. PubMed ID: 19194124
[TBL] [Abstract][Full Text] [Related]
13. Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC).
Link K; Happich K; Schirner I; Jüngert B; Brückl V; Männlein G; Brückl WM; Merkel S; Göhl J; Hohenberger W; Hahn EG; Wein A
Anticancer Res; 2004; 24(1):385-91. PubMed ID: 15015625
[TBL] [Abstract][Full Text] [Related]
14. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A
J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419
[TBL] [Abstract][Full Text] [Related]
15. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer.
Ducreux M; Ychou M; Laplanche A; Gamelin E; Lasser P; Husseini F; Quenet F; Viret F; Jacob JH; Boige V; Elias D; Delperro JR; Luboinski M;
J Clin Oncol; 2005 Aug; 23(22):4881-7. PubMed ID: 16009952
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
17. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure.
Boige V; Malka D; Elias D; Castaing M; De Baere T; Goere D; Dromain C; Pocard M; Ducreux M
Ann Surg Oncol; 2008 Jan; 15(1):219-26. PubMed ID: 17896145
[TBL] [Abstract][Full Text] [Related]
18. Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data.
Fischel JL; Etienne MC; Formento P; Milano G
Clin Cancer Res; 1998 Oct; 4(10):2529-35. PubMed ID: 9796987
[TBL] [Abstract][Full Text] [Related]
19. Folinic acid (FA) plus 5-fluorouracil (FU) in progressive advanced colorectal cancer.
Wilke H; Schmoll HJ; Schöber C; Stahl M; Preusser P; Freund M; Poliwoda H
Biomed Pharmacother; 1988; 42(6):373-80. PubMed ID: 3064821
[TBL] [Abstract][Full Text] [Related]
20. Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy.
Fountzilas G; Gossios K; Zisiadis A; Svarna E; Skarlos D; Pavlidis N
Med Pediatr Oncol; 1996 May; 26(5):305-17. PubMed ID: 8614363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
